Sister chromatid exchanges in lymphocyte cultures of patients previously treated with dibromodulcitol.
Acute non-lymphatic leukaemia and myelodysplasia occur in a larger percentage of patients treated with dibromodulcitol (DBD) than in patients treated with other cytostatics. Sister chromatid exchanges (SCE) in the lymphocytes in peripheral blood as well as other haematological parameters were measured in women with breast cancer to investigate whether women who had previously been treated with DBD as a part of their treatment regime had an increased frequency of SCE or another haematological abnormality attributable to DBD. SCE levels were elevated in women treated with DBD as well as in those treated with other cytostatics compared to the untreated control group. All other haematological parameters were normal. There was no significant difference in the number of SCEs between the patients who received DBD and those treated with other cytostatics. The increased frequencies of SCE in the treated patients are attributable to various cytostatic agents, and there is no significant permanent increase in the frequency of SCE after exposure to DBD.
Ansell
S M
SM
Department of Medical Oncology, University of Pretoria, Republic of South Africa.
Jansen van Rensburg
C E
CE
Rapoport
B L
BL
Gresse
P
P
Cloete
E V
EV
van Staden
A M
AM
Stevens
K
K
Falkson
C I
CI
Falkson
G
G
D001943:Breast Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000235:genetics; D005260:Female; D006801:Humans; D008214:Lymphocytes / Q000648:ultrastructure; D008936:Mitolactol / Q000009:adverse effects* / Q000627:therapeutic use; D009362:Neoplasm Metastasis; D012854:Sister Chromatid Exchange
D008936:Mitolactol